Identifying Risk-De-Escalating Markers in PREVENT-Defined Intermediate-Risk Older Adults: Insights From ASPREE
Authors' conclusion
Adding polygenic risk for coronary artery disease to the PREVENT equations may further personalize risk estimates and support clinical decision-making for older adults at intermediate risk for ASCVD events.
Study context
- Population
- Intermediate-risk older adults aged ≥70 years (10-year PREVENT-estimated atherosclerotic cardiovascular disease (ASCVD) risk, 7.5% to 20%) from ASPREE, a randomized trial of low-dose aspirin versus placebo in healthy older adults free of prior cardiovascular events at enrollmentparticipants included, 725 (9.3%) experienced ASCVD events
- Participants
- 7,764 adults
- Comparison
- Each marker relative to a baseline model incorporating variables included in the PREVENT equation
Primary result
As reported in the abstract
ASCVD events · median follow-up of 10.3 years
Participants experiencing ASCVD events
725 participants
9.3%
Further findings
| Outcome | ΔC | P value |
|---|---|---|
| Reclassification performance of Q1 polygenic risk for coronary artery disease · most powerful marker for down-grading risk | +1.44% | P = 0.004 |
| Reclassification performance of Q1 hs-TnI · second-best performance | +0.71% |
- Reclassification performance of Q1 polygenic risk for coronary artery disease — risk reduction
- 37%
- Reclassification performance of Q1 polygenic risk for coronary artery disease — diagnostic likelihood ratio
- 0.627
- Reclassification performance of Q1 polygenic risk for coronary artery disease — nonevents correctly reclassified downward
- 25.9%
- Reclassification performance of Q1 polygenic risk for coronary artery disease — net reclassification index
- 0.101
- Reclassification performance of Q1 hs-TnI — diagnostic likelihood ratio
- 0.727
- Reclassification performance of Q1 hs-TnI — net reclassification index
- 0.075
Original publication
Identifying Risk-De-Escalating Markers in PREVENT-Defined Intermediate-Risk Older Adults: Insights From ASPREE. Circ Popul Health Outcomes. Published 2 July 2026. doi:10.
Summarised from the published abstract; every number is checked against it